CA2303591A1 - Methode et compositions pour prevenir ou reduire l'infection par le vih - Google Patents

Methode et compositions pour prevenir ou reduire l'infection par le vih Download PDF

Info

Publication number
CA2303591A1
CA2303591A1 CA 2303591 CA2303591A CA2303591A1 CA 2303591 A1 CA2303591 A1 CA 2303591A1 CA 2303591 CA2303591 CA 2303591 CA 2303591 A CA2303591 A CA 2303591A CA 2303591 A1 CA2303591 A1 CA 2303591A1
Authority
CA
Canada
Prior art keywords
preventing
lapase
reducing hiv
compositions
hiv infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2303591
Other languages
English (en)
Other versions
CA2303591C (fr
Inventor
Gabriel Pulido-Cejudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbreal Therodiagnostics Canada Holding Corp
Canada Minister of Health
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002267481A external-priority patent/CA2267481A1/fr
Application filed by Individual filed Critical Individual
Priority to CA 2303591 priority Critical patent/CA2303591C/fr
Publication of CA2303591A1 publication Critical patent/CA2303591A1/fr
Application granted granted Critical
Publication of CA2303591C publication Critical patent/CA2303591C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2303591 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih Expired - Fee Related CA2303591C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2303591 CA2303591C (fr) 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,267,481 1999-03-30
CA002267481A CA2267481A1 (fr) 1999-03-30 1999-03-30 Interdependance critique : du role de l'oestrogene dans le cancer du sein a la sensibilite des femmes a l'infection par le vih
CA 2303591 CA2303591C (fr) 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih

Publications (2)

Publication Number Publication Date
CA2303591A1 true CA2303591A1 (fr) 2000-09-11
CA2303591C CA2303591C (fr) 2002-12-17

Family

ID=25680865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2303591 Expired - Fee Related CA2303591C (fr) 1999-03-30 2000-03-30 Methode et compositions pour prevenir ou reduire l'infection par le vih

Country Status (1)

Country Link
CA (1) CA2303591C (fr)

Also Published As

Publication number Publication date
CA2303591C (fr) 2002-12-17

Similar Documents

Publication Publication Date Title
CA2173328A1 (fr) Inhibiteurs de la protease du vih
AU3413100A (en) Method and compositions for preventing or reducing hiv infection by use of inhibitors for leucine aminopeptidase
AU2002310156A1 (en) 1,4-disubstituted benzo-fused cycloalkyl urea compounds
WO2004096818A3 (fr) Procede et compositions pour l'identification de composes therapeutiques anti-vih
RU95106823A (ru) Сукциноиламиногидроксиэтиламиносульфонамиды, фармацевтическая композиция, способ ингибирования ретровирусной протеазы, способ лечения ретровирусной инфекции способ лечения спида
AU5729196A (en) Soluble, active hepatitis c virus protease
WO2001077091A3 (fr) Inhibiteurs de polymerases ns5b vhc
WO2001010456A3 (fr) Peptides bloquant les infections virales et procedes d'utilisation correspondants
WO2004037784A3 (fr) Pyrrolidones ayant une activité anti-vih
AU5694901A (en) Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission
AU2658695A (en) N-(3-amino-2-hydroxybutyl)sulphonamide derivatives as hiv protease inhibitors
WO2003015708A3 (fr) Traitement de l'infection par le vih et composition a cet effet
WO1995014011A3 (fr) Derives de la 5,6-dihydropyrone en tant qu'inhibiteurs de la protease et agents antiviraux
AU6087194A (en) Hiv protease inhibitors
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
AU2003217604A1 (en) Method of treating hiv infection by preventing interaction of cd4 and gp120
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
AU2002326925A1 (en) Process for preparing protease inhibitor intermediates
CA2303591A1 (fr) Methode et compositions pour prevenir ou reduire l'infection par le vih
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2002365168A1 (en) Method and composition for treating and preventing hiv infection and aids
EP0379295A3 (fr) Anticorps antitryptase et composition pour le traitement du sida utilisant cet anticorps
CA2345896A1 (fr) Procede de modulation de l'activite fonctionnelle du canal ionique
ATE294790T1 (de) Chlormethylierung von thiophene

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130402